Emerging non-invasively collected genomic and proteomic biomarkers for the early diagnosis of oral squamous cell carcinoma (OSCC)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Oral cancer is the sixth most common cancer worldwide ahead of Hodgkin's lymphoma, leukemia, brain, stomach, or ovarian cancers, with about 37,000 Americans being diagnosed annually. More than 90% of oral cancers are oral squamous cell carcinomas (OSCC). While the overall 5-year survival rate is about 50%, the survival rate when diagnosed early and treated as localized tumors is as high as 90%. Currently the gold standard for diagnosis of OSCC is early visual detection of a suspicious oral lesion followed by scalpel biopsy with adjunct histology. However, there are multiple limitations associated with biopsies: being invasive clinicians are hesitant to perform them, and patients may not agree to them due to the pain and discomfort of the procedure; the following histology requires expert analysis and is therefore expensive; and issues such as under-sampling add uncertainty to diagnosis. An ideal alternative to scalpel biopsy would be non-invasively collected samples containing biomarkers which can distinguish between oral pre-malignant lesions (OPMLs) and OSCC, and potentially predict the transition from pre-malignancy to malignancy. Methods for sampling and discovering biomarkers of OSCC in a non-invasive fashion have been emerging, including those focusing on whole saliva and cells and other specimens collected directly from oral lesions. These samples are ideally suited for system-wide analysis using genomic and proteomic technologies for biomarker discovery. Here, we describe the current state of the clinical diagnosis of oral cancer, with an emphasis on emerging genomic and proteomic strategies seeking to identify non-invasively collected biomarkers that could improve the early diagnosis of OPML transition to OSCC.

Original languageEnglish (US)
Title of host publicationSquamous Cell Carcinoma
PublisherNova Science Publishers, Inc.
Pages197-210
Number of pages14
ISBN (Print)9781612099293
StatePublished - Dec 1 2012

Fingerprint

Biomarkers
Proteomics
Mouth Neoplasms
Early Diagnosis
Squamous Cell Carcinoma
Biopsy
Histology
Neoplasms
Survival Rate
Sampling
Oral Diagnosis
Hodgkin Disease
Saliva
Brain Neoplasms
Ovarian Neoplasms
Stomach Neoplasms
Uncertainty
Tumors
Brain
Leukemia

Keywords

  • Biomarkers
  • DNA methylation/hypermethylation
  • Genomics
  • Mass spectrometry
  • Oral pre-malignant lesion (OPML)
  • Oral squamous cell carcinoma (OSCC)
  • Proteomics
  • Sensitivity
  • Specificity
  • Whole saliva

Cite this

Emerging non-invasively collected genomic and proteomic biomarkers for the early diagnosis of oral squamous cell carcinoma (OSCC). / Kooren, Joel A.; Rhodus, Nelson L.; Griffin, Timothy J.

Squamous Cell Carcinoma. Nova Science Publishers, Inc., 2012. p. 197-210.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{770af6cdd6744ec9b78d0cf25e9e56bc,
title = "Emerging non-invasively collected genomic and proteomic biomarkers for the early diagnosis of oral squamous cell carcinoma (OSCC)",
abstract = "Oral cancer is the sixth most common cancer worldwide ahead of Hodgkin's lymphoma, leukemia, brain, stomach, or ovarian cancers, with about 37,000 Americans being diagnosed annually. More than 90{\%} of oral cancers are oral squamous cell carcinomas (OSCC). While the overall 5-year survival rate is about 50{\%}, the survival rate when diagnosed early and treated as localized tumors is as high as 90{\%}. Currently the gold standard for diagnosis of OSCC is early visual detection of a suspicious oral lesion followed by scalpel biopsy with adjunct histology. However, there are multiple limitations associated with biopsies: being invasive clinicians are hesitant to perform them, and patients may not agree to them due to the pain and discomfort of the procedure; the following histology requires expert analysis and is therefore expensive; and issues such as under-sampling add uncertainty to diagnosis. An ideal alternative to scalpel biopsy would be non-invasively collected samples containing biomarkers which can distinguish between oral pre-malignant lesions (OPMLs) and OSCC, and potentially predict the transition from pre-malignancy to malignancy. Methods for sampling and discovering biomarkers of OSCC in a non-invasive fashion have been emerging, including those focusing on whole saliva and cells and other specimens collected directly from oral lesions. These samples are ideally suited for system-wide analysis using genomic and proteomic technologies for biomarker discovery. Here, we describe the current state of the clinical diagnosis of oral cancer, with an emphasis on emerging genomic and proteomic strategies seeking to identify non-invasively collected biomarkers that could improve the early diagnosis of OPML transition to OSCC.",
keywords = "Biomarkers, DNA methylation/hypermethylation, Genomics, Mass spectrometry, Oral pre-malignant lesion (OPML), Oral squamous cell carcinoma (OSCC), Proteomics, Sensitivity, Specificity, Whole saliva",
author = "Kooren, {Joel A.} and Rhodus, {Nelson L.} and Griffin, {Timothy J.}",
year = "2012",
month = "12",
day = "1",
language = "English (US)",
isbn = "9781612099293",
pages = "197--210",
booktitle = "Squamous Cell Carcinoma",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Emerging non-invasively collected genomic and proteomic biomarkers for the early diagnosis of oral squamous cell carcinoma (OSCC)

AU - Kooren, Joel A.

AU - Rhodus, Nelson L.

AU - Griffin, Timothy J.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Oral cancer is the sixth most common cancer worldwide ahead of Hodgkin's lymphoma, leukemia, brain, stomach, or ovarian cancers, with about 37,000 Americans being diagnosed annually. More than 90% of oral cancers are oral squamous cell carcinomas (OSCC). While the overall 5-year survival rate is about 50%, the survival rate when diagnosed early and treated as localized tumors is as high as 90%. Currently the gold standard for diagnosis of OSCC is early visual detection of a suspicious oral lesion followed by scalpel biopsy with adjunct histology. However, there are multiple limitations associated with biopsies: being invasive clinicians are hesitant to perform them, and patients may not agree to them due to the pain and discomfort of the procedure; the following histology requires expert analysis and is therefore expensive; and issues such as under-sampling add uncertainty to diagnosis. An ideal alternative to scalpel biopsy would be non-invasively collected samples containing biomarkers which can distinguish between oral pre-malignant lesions (OPMLs) and OSCC, and potentially predict the transition from pre-malignancy to malignancy. Methods for sampling and discovering biomarkers of OSCC in a non-invasive fashion have been emerging, including those focusing on whole saliva and cells and other specimens collected directly from oral lesions. These samples are ideally suited for system-wide analysis using genomic and proteomic technologies for biomarker discovery. Here, we describe the current state of the clinical diagnosis of oral cancer, with an emphasis on emerging genomic and proteomic strategies seeking to identify non-invasively collected biomarkers that could improve the early diagnosis of OPML transition to OSCC.

AB - Oral cancer is the sixth most common cancer worldwide ahead of Hodgkin's lymphoma, leukemia, brain, stomach, or ovarian cancers, with about 37,000 Americans being diagnosed annually. More than 90% of oral cancers are oral squamous cell carcinomas (OSCC). While the overall 5-year survival rate is about 50%, the survival rate when diagnosed early and treated as localized tumors is as high as 90%. Currently the gold standard for diagnosis of OSCC is early visual detection of a suspicious oral lesion followed by scalpel biopsy with adjunct histology. However, there are multiple limitations associated with biopsies: being invasive clinicians are hesitant to perform them, and patients may not agree to them due to the pain and discomfort of the procedure; the following histology requires expert analysis and is therefore expensive; and issues such as under-sampling add uncertainty to diagnosis. An ideal alternative to scalpel biopsy would be non-invasively collected samples containing biomarkers which can distinguish between oral pre-malignant lesions (OPMLs) and OSCC, and potentially predict the transition from pre-malignancy to malignancy. Methods for sampling and discovering biomarkers of OSCC in a non-invasive fashion have been emerging, including those focusing on whole saliva and cells and other specimens collected directly from oral lesions. These samples are ideally suited for system-wide analysis using genomic and proteomic technologies for biomarker discovery. Here, we describe the current state of the clinical diagnosis of oral cancer, with an emphasis on emerging genomic and proteomic strategies seeking to identify non-invasively collected biomarkers that could improve the early diagnosis of OPML transition to OSCC.

KW - Biomarkers

KW - DNA methylation/hypermethylation

KW - Genomics

KW - Mass spectrometry

KW - Oral pre-malignant lesion (OPML)

KW - Oral squamous cell carcinoma (OSCC)

KW - Proteomics

KW - Sensitivity

KW - Specificity

KW - Whole saliva

UR - http://www.scopus.com/inward/record.url?scp=84891997169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891997169&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84891997169

SN - 9781612099293

SP - 197

EP - 210

BT - Squamous Cell Carcinoma

PB - Nova Science Publishers, Inc.

ER -